| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282458 | Clinical Gastroenterology and Hepatology | 2013 | 9 Pages |
Abstract
FCM prevents recurrence of anemia in patients with IBD, compared with placebo. Nevertheless, the high rate of anemia recurrence warrants optimization of the frequency and requirements for FCM treatment. Clinical Trial number: NCT00810004.
Keywords
TSATper-protocol setIBDQSF-36QOLIBDFASFCMQuality of lifePpsTEAEIntravenous ironferric carboxymaltoseTransferrin saturationCrohn's diseaseInflammatory bowel diseasefull analysis settreatment emergent adverse eventAdverse eventsconfidence intervalHemoglobinInflammatory Bowel Disease QuestionnaireUlcerative colitisulcerative colitis.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Rayko Evstatiev, Olga Alexeeva, Bernd Bokemeyer, Ivan Chopey, Marcel Felder, Maja Gudehus, Tariq Iqbal, Igor Khalif, Philippe Marteau, Jürgen Stein, Christoph Gasche, FERGI Study Group FERGI Study Group,